<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00222443</url>
  </required_header>
  <id_info>
    <org_study_id>JEC Toca One</org_study_id>
    <nct_id>NCT00222443</nct_id>
    <nct_alias>NCT00277719</nct_alias>
  </id_info>
  <brief_title>Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy</brief_title>
  <official_title>Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <brief_summary>
    <textblock>
      Determine toxicity and maximum tolerated dose of escalating daily protracted irinotecan, with&#xD;
      weekly vincristine, temozolomide and vantin; to evaluate the feasibility of repetitive cycles&#xD;
      of this chemotherapy and to estimate the response rate to this combination in children and&#xD;
      adolescents with recurrent solid tumors and lymphomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Determine toxicity and maximum tolerated dose of escalating daily protracted irinotecan, with&#xD;
      weekly vincristine, temozolomide and vantin; to evaluate the feasibility of repetitive cycles&#xD;
      of this chemotherapy and to estimate the response rate to this combination in children and&#xD;
      adolescents with recurrent solid tumors and lymphomas.&#xD;
&#xD;
      Temozolomide is given by mouth one hour prior to each daily irinotecan dose days 1-5 of each&#xD;
      cycle. 100 mg/m2/day. Irinotecan is given IV in dose escalation (minimum of 3 and up to 6&#xD;
      patients per cohort) starting at 15 mg/m2/day daily for 5 days for 2 weeks. Vincristin is&#xD;
      given IV 1.5 mg/m2/dose (max dose 2mg) days 1 and 8 of each cycle. Vantin is given 10&#xD;
      mg/kg/day divided in 2 oral doses (max dose 400 mg/day) started 48 hours prior to the start&#xD;
      of each treatment cycle and continued for 48 hours after last irinotecan dose. Cycle repeated&#xD;
      every 28 days.&#xD;
&#xD;
      Therapy will continue for a minimum of two cycles unless there is progression of disease or&#xD;
      unacceptable toxicity and may be continued as long as patient tolerates therapy and there is&#xD;
      continued disease control up to one year of therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine toxicity and maximum tolerated dose of escalating daily protracted irinotecan.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate feasibility of repetitive cycles of this combination .</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimate response rate in children and adolescents with recurrent solid tumors and lymphomas.</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Lymphomas</condition>
  <condition>Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Under age 21 years at time of study entry&#xD;
&#xD;
          -  Malignant solid tumor, including CNS tumors and lymphomas&#xD;
&#xD;
          -  Recurrent or refractory disease not amenable to other potentially curative therapies&#xD;
&#xD;
          -  At least three weeks since last myelosuppressive chemotherapy &gt; 6 months from&#xD;
             allogeneic stem cell transplant&#xD;
&#xD;
          -  Adequate renal and hepatic function&#xD;
&#xD;
          -  Adequate peripheral blood counts unless bone marrow is involved&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with leukemia not eligible&#xD;
&#xD;
          -  Patients with uncontrolled infection excluded&#xD;
&#xD;
          -  Patients who have received more than 4 prior chemotherapies&#xD;
&#xD;
          -  Patients who are receiving P450 enzyme-inducing anticonvulsants&#xD;
&#xD;
          -  Patients who are receiving any other cancer chemotherapy or any other investigational&#xD;
             agent&#xD;
&#xD;
          -  Possible pregnancy will be excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William H Meyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oklahoma University Health Sciences Center-Jimmy Everest Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>September 20, 2005</study_first_submitted>
  <study_first_submitted_qc>September 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>September 19, 2008</last_update_submitted>
  <last_update_submitted_qc>September 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2008</last_update_posted>
  <keyword>Recurrent solid tumors</keyword>
  <keyword>recurrent lymphomas</keyword>
  <keyword>Pediatrics</keyword>
  <keyword>Adolescents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

